Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders.

Reid told BioCentury that Decibel Therapeutics Inc.'s reorganization deprioritizes its early R&D in hearing protection and its tinnitus and synaptopathy-induced hearing loss programs. New targets and products entering the company's pipeline will be regenerative therapies for hearing loss and balance disorders, but the company will continue developing its clinical-stage therapy for hearing protection and its lead gene therapy for congenital deafness...